TrivarX (TRI.AX) ASX up 36.36% pre-market 12 Feb 2026: earnings catalyst ahead

TRI.AX stock jumped 36.36% pre-market to A$0.03 on 12 Feb 2026, with volume spiking to 6,681,616 shares as traders positioned ahead of an earnings update. The move made TrivarX Limited (TRI.AX) one of the top gainers on the ASX in early trading. Investors are watching the company’s upcoming results on 27 Feb 2026 and short-term momentum: the 50-day average is A$0.020 and the 200-day average is A$0.015. Meyka AI’s market tools flag the stock as volatile but actionable for short-term traders.

Price action and volume: TRI.AX stock spikes pre-market

TrivarX (TRI.AX) on the ASX opened A$0.026 and climbed to A$0.03 pre-market, a +36.36% intraday move versus the previous close of A$0.022. Volume was 6,681,616 versus an average of 1,324,369, about 5.05x normal, signalling a genuine liquidity event rather than a thin-market blip.

Catalyst and news drivers: earnings and corporate updates

The primary near-term catalyst is an earnings announcement scheduled for 27 Feb 2026. Market participants are pricing updates to revenue recognition and any US commercial traction. TrivarX is a health technology company developing AI-driven screening devices for behavioural health, operating in Australia and the United States, and any revenue/contract detail would explain strong pre-market appetite.

Financial snapshot and valuation: what the numbers say

TrivarX reports a market capitalisation of A$28,842,337.00 with 1,153,693,464 shares outstanding. Trailing metrics show no EPS reported and a negative PE (reported as -13.24), while price-to-book sits at 0.99, indicating the market values the company roughly in line with book value. Cash per share is A$0.002 and current ratio is 1.86, showing a short runway but low leverage (debt-to-equity 0.01).

Technical and sector context for TRI.AX stock

Technically, ADX reads 66.67, indicating a strong short-term trend, and RSI is 51.85, suggesting neutral momentum. The Healthcare sector on the ASX is up 0.31% YTD and 13.68% 6M, which supports appetite for mid-cap health-tech stories. Short-term support sits near the 50-day average A$0.020 and resistance near the year high A$0.035.

Meyka grade and model forecast for TRI.AX stock

Meyka AI rates TRI.AX with a score out of 100: 61.88 / 100 (Grade B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of A$0.02, which implies a -33.33% move from the current A$0.03; forecasts are model-based projections and not guarantees.

Risks and catalysts to watch for TRI.AX stock

Key risks include limited revenue visibility, ongoing losses (negative ROE -7.84%), heavy intangible assets (intangibles to assets 89.11%), and high days-payable metrics. Catalysts that could lift the stock materially are stronger-than-expected revenue disclosure on 27 Feb 2026, US market adoption updates, or strategic partnerships.

Final Thoughts

TRI.AX stock is a clear short-term momentum story after a 36.36% pre-market move to A$0.03 on 12 Feb 2026 driven by heavy volume. Financials show tight cash per share (A$0.002) and negative profitability metrics, which keeps the risk profile elevated despite low leverage. Meyka AI’s grade (61.88, B / HOLD) and model forecast (monthly A$0.02) point to divergence between technical momentum and fundamental outlook; the model implies -33.33% downside to the forecast figure from the current price. For traders, the stock offers liquidity and volatility; for longer-term investors the stock needs clearer revenue proof and post-earnings guidance before a buy recommendation. We set realistic price targets: conservative A$0.02, base A$0.04, and bull A$0.06. All forecasts are model-based projections and not guarantees, and investors should watch the 27 Feb 2026 earnings release for the next directional signal. For company details see the official site TrivarX and public profile image company profile. Meyka AI is an AI-powered market analysis platform that tracks this stock in real time.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.